跳至主要内容
临床试验/NL-OMON52907
NL-OMON52907招募中不适用

The effect of targeted nutrient supplementation on physical activity and health related quality of life in COPD - NUTRECOVER trial

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 198 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
198

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • COPD patients NUTRECOVER trial:
  • - COPD patients with moderate to very severe disease stage according to GOLD
  • criteria (i.e. GOLD stage II-IV);
  • - Medically stable in the opinion of the investigator.
  • Reference group microbiome study:
  • - Lung function: FEV1/FVC > 0.7
  • - Medically stable in the opinion of the investigator.

排除标准

  • COPD patients NUTRECOVER trial:
  • Exclusion criteria indicated with an asterisk (*) are also exclusion criteria
  • for the subjects in the reference group for the microbiome study.
  • - Age <18 years;*
  • - Allergy or intolerance to components of the study product;
  • - Investigator*s uncertainty about the willingness or ability of the patient to
  • comply with the protocol requirements (e.g. leg amputation) or patients
  • suffering from other acute or unstable chronic diseases that will compromise
  • the study outcome (e.g. active cancer requiring treatment);*
  • - Participation in any other study involving investigational or marketed
  • products concomitantly or within four weeks prior to entry into the study;*
  • - Patients with terminal illness;*
  • - Recent hospital admission (<4 weeks prior to the start of the study);*
  • - COPD patients with temporary oral steroid or antibiotics use due to a COPD
  • exacerbation in the last 4 weeks or subjects in the reference group with
  • antibiotics use for any reason in the last 4 weeks;
  • - Lung malignancy in the previous 5 years;*
  • - Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer*s
  • disease, Parkinson*s disease, Huntington*s chorea, frontotemporal dementia) in
  • the medical records;*
  • - Recent diagnosis of cerebral conditions (< 1 year e.g. cerebral infarction,
  • hemorrhage, brain tumors, transient ischemic attack) in the medical records;*
  • - Any medical condition that significantly interferes with digestion and/or
  • gastro-intestinal function (e.g. short bowel syndrome, inflammatory bowel
  • disease, gastric ulcers, gastritis, (gastro)-enteritis, GI cancer as judged by
  • the investigator;*
  • -Subjects in the reference group in the microbiome study: diagnosis of any
  • chronic lung disease.

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验